Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CYP2J2 CRISPR/Cas9 KO Plasmid (h): sc-402955
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CYP2J2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CYP2J2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CYP2J2 Antibody (D-6): sc-137127
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CYP2J2 CRISPR/Cas9 KO Plasmid (h) | sc-402955 | 20 µg | $397.00 |
Overview
CYP2J2 encodes a microsomal cytochrome P450 monooxygenase that catalyzes NADPH-dependent oxidation of endogenous lipids and xenobiotics, with notable epoxygenase activity toward arachidonic acid to generate epoxyeicosatrienoic acids (EETs). These metabolites contribute to regulation of vascular tone, inflammatory signaling, cellular proliferation, and oxidative stress responses, linking CYP2J2 activity to eicosanoid and lipid mediator pathways. CYP2J2 expression in cardiovascular and extrahepatic tissues supports roles in endothelial function and metabolic homeostasis, and altered expression or activity has been associated with cardiometabolic and inflammatory phenotypes. In cancer biology, CYP2J2-dependent lipid signaling has been investigated in relation to tumor cell survival, migration, and microenvironmental crosstalk, making it a useful target for mechanistic studies.
CYP2J2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CYP2J2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CYP2J2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CYP2J2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CYP2J2 protein expression.
This CRISPR knockout system enables efficient generation of CYP2J2-deficient cell models for investigation of CYP2J2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CYP2J2 exon(s) critical for CYP2J2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CYP2J2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CYP2J2 CRISPR/Cas9 KO Plasmid (h) and CYP2J2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CYP2J2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CYP2J2 HDR Plasmid (h) and CYP2J2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CYP2J2 homology arms to support homology-directed repair at defined CYP2J2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.